{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:01:10Z","timestamp":1790614870393,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010891","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000}}],"reference-count":79,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010891.pub2","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T15:31:43Z","timestamp":1563377503000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Genetic testing for prevention of severe drug-induced skin rash"],"prefix":"10.1002","volume":"2019","author":[{"given":"Ana","family":"Alfirevic","sequence":"first","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Centre for Personalised Medicine, Block A: Waterhouse Building 1-5 Brownlow Street Liverpool UK L69 3GE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munir","family":"Pirmohamed","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Centre for Personalised Medicine, Block A: Waterhouse Building 1-5 Brownlow Street Liverpool UK L69 3GE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Marinovic","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, School of Medicine, University of Zagreb; Department of Dermatology and Venereology; Salata 4 Zagreb Croatia 10000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Harcourt-Smith","sequence":"additional","affiliation":[{"name":"The University of Nottingham; c\/o Cochrane Skin Group; A103, King's Meadow Campus Lenton Lane Nottingham UK NG7 2NR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"University of Liverpool; Centre for Medical Statistics and Health Evaluation; Shelley's Cottage Brownlow Street Liverpool UK L69 3 GS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess E","family":"Cooper","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7,17]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD010891.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/pst.286","article-title":"PREDICT-1 (CNA106030): The first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events","volume":"7","author":"Hughes","year":"2008","journal-title":"Pharmaceutical Statistics"},{"issue":"6","key":"10.1002\/14651858.CD010891.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010891.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"Azuma","year":"2013","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD010891.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S1470-2045(11)70094-8","article-title":"TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994\/BIG 1-00): a randomised phase 3 trial","volume":"12","author":"Bonnefoi","year":"2011","journal-title":"Lancet Oncology"},{"issue":"8","key":"10.1002\/14651858.CD010891.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1373\/clinchem.2009.127894","article-title":"New testing approach in HLA genotyping helps overcome barriers in effective clinical practice","volume":"55","author":"Cheng","year":"2009","journal-title":"Clinical Chemistry"},{"key":"10.1002\/14651858.CD010891.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/pgpm.586446","article-title":"A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study","volume":"8","author":"Damronglerd","year":"2015","journal-title":"Pharmacogenomics and Personalized Medicine"},{"issue":"6","key":"10.1002\/14651858.CD010891.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2217\/pgs.11.32","article-title":"A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to axathioprine treatment: the TARGET study","volume":"12","author":"Newman","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"20","key":"10.1002\/14651858.CD010891.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1158\/1078-0432.CCR-14-0800","article-title":"Gene signature-guided Dasatinib therapy in metastatic breast cancer","volume":"20","author":"Pusztai","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"27","key":"10.1002\/14651858.CD010891.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD010891.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1470-2045(13)70163-3","article-title":"Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial","volume":"14","author":"Seymour","year":"2013","journal-title":"Lancet Oncology"},{"issue":"13","key":"10.1002\/14651858.CD010891.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/QAD.0b013e32830719aa","article-title":"First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America","volume":"22","author":"Young","year":"2008","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD010891.pub2-BIB0012|cit12","first-page":"S103","article-title":"Personalized thiopurine dosing based on TPMT genotyping reduces leucopenia occurrence and results in cost-savings in IBD patients: A randomized trial in the Netherlands","volume":"97","author":"Coenen","year":"2015","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD010891.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/clpt.2013.55","article-title":"HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children","volume":"94","author":"Amstutz","year":"2013","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD010891.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jnci\/81.2.107","article-title":"Publication bias and dissemination of clinical research","volume":"81","author":"Begg","year":"1989","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD010891.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-7-72","article-title":"Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist?","volume":"7","author":"Bouvresse","year":"2012","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"9","key":"10.1002\/14651858.CD010891.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/cid\/cit021","article-title":"Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population","volume":"56","author":"Carr","year":"2013","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD010891.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FPC.0b013e32831d0faf","article-title":"HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients","volume":"19","author":"Chantarangsu","year":"2009","journal-title":"Pharmacogenetics and Genomics"},{"issue":"12","key":"10.1002\/14651858.CD010891.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD010891.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/epi.12217","article-title":"HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese","volume":"54","author":"Cheung","year":"2013","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD010891.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/archdischild-2013-304767","article-title":"Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore","volume":"99","author":"Chong","year":"2014","journal-title":"Archives of Disease in Childhood"},{"issue":"6982","key":"10.1002\/14651858.CD010891.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"issue":"7","key":"10.1002\/14651858.CD010891.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1365-4632.2010.04481.x","article-title":"Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia","volume":"49","author":"Ding","year":"2010","journal-title":"International Journal of Dermatology"},{"issue":"7124","key":"10.1002\/14651858.CD010891.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/bmj.316.7124.61","article-title":"Bias in location and selection of studies","volume":"316","author":"Egger","year":"1998","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010891.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3389\/fphar.2019.00149","article-title":"A screening test for HLA-B*15:02 in a large United States patient cohort identifies broader risk of carbamazepine-induced adverse events","volume":"10","author":"Fang","year":"2019","journal-title":"Frontiers in Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD010891.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1089\/aid.2011.0107","article-title":"HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients","volume":"28","author":"Gao","year":"2012","journal-title":"AIDS Research and Human Retroviruses"},{"issue":"2","key":"10.1002\/14651858.CD010891.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAD.0b013e32801199d9","article-title":"HLA-Cw8 primarily associated with hypersensitivity to nevirapine","volume":"21","author":"Gatanaga","year":"2007","journal-title":"AIDS"},{"issue":"9312","key":"10.1002\/14651858.CD010891.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010891.pub2-BIB0028|cit28","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration Available from training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD010891.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00008571-200406000-00002","article-title":"Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity","volume":"14","author":"Hughes","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"2","key":"10.1002\/14651858.CD010891.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/phgs.5.2.203.27481","article-title":"Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations","volume":"5","author":"Hughes","year":"2004","journal-title":"Pharmacogenomics"},{"issue":"11","key":"10.1002\/14651858.CD010891.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1002\/14651858.CD010891.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenetics and Genomics"},{"issue":"3","key":"10.1002\/14651858.CD010891.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/pgs.09.162","article-title":"Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese","volume":"11","author":"Hung","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"7404","key":"10.1002\/14651858.CD010891.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"issue":"11","key":"10.1002\/14651858.CD010891.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1002\/14651858.CD010891.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD010891.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/FPC.0b013e32832c347d","article-title":"High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients","volume":"19","author":"Kazeem","year":"2009","journal-title":"Pharmacogenetics and Genomics"},{"issue":"3","key":"10.1002\/14651858.CD010891.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1365-2222.2004.02197.x","article-title":"The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria","volume":"35","author":"Kim","year":"2005","journal-title":"Clinical and Experimental Allergy"},{"issue":"3","key":"10.1002\/14651858.CD010891.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1533-2500.2011.00479.x","article-title":"HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain","volume":"12","author":"Kulkantrakorn","year":"2012","journal-title":"Pain Practice"},{"issue":"11","key":"10.1002\/14651858.CD010891.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1289\/ehp.10325","article-title":"HLA-B*1301 as a biomarker for genetic susceptibility to hypersensitivity dermatitis induced by trichloroethylene among workers in China","volume":"115","author":"Li","year":"2007","journal-title":"Environmental Health Perspectives"},{"key":"10.1002\/14651858.CD010891.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-6405-6-22","article-title":"HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients","volume":"6","author":"Likanonsakul","year":"2009","journal-title":"AIDS Research and Therapy"},{"issue":"12","key":"10.1002\/14651858.CD010891.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/01.aids.0000238408.82947.09","article-title":"HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients","volume":"20","author":"Littera","year":"2006","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD010891.pub2-BIB0043|cit43","unstructured":"Liu H Wang Z Bao F Wang C Sun L Zhang H Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy JAMA Dermatology 10.1001\/jamadermatol.2018.5360"},{"issue":"12","key":"10.1002\/14651858.CD010891.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"issue":"9308","key":"10.1002\/14651858.CD010891.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD010891.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"issue":"9566","key":"10.1002\/14651858.CD010891.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD010891.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1073\/pnas.0307067101","article-title":"Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant","volume":"101","author":"Martin","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1002\/14651858.CD010891.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"issue":"5","key":"10.1002\/14651858.CD010891.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/clpt.2014.38","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update","volume":"95","author":"Martin","year":"2014","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"12","key":"10.1002\/14651858.CD010891.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD010891.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4103\/0378-6323.57718","article-title":"Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians","volume":"75","author":"Mehta","year":"2009","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"7","key":"10.1002\/14651858.CD010891.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jamaneurol.2018.0278","article-title":"Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population","volume":"75","author":"Mushiroda","year":"2018","journal-title":"JAMA Neurology"},{"issue":"5","key":"10.1002\/14651858.CD010891.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Human Molecular Genetics"},{"issue":"5","key":"10.1002\/14651858.CD010891.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1067\/mjd.2001.117854","article-title":"Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype","volume":"45","author":"Ozkaya-Bayazit","year":"2001","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD010891.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2710.2008.00961.x","article-title":"What do we know about the genetics of aspirin intolerance?","volume":"33","author":"Palikhe","year":"2008","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD010891.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jaip.2018.12.012","article-title":"Efficacy of the HLA-B*58:01 screening test in preventing allopurinol-induced severe cutaneous adverse reactions in patients with chronic renal insufficiency - a prospective study","volume":"7","author":"Park","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology and Practice"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD010891.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0190-9622(97)80347-7","article-title":"Fixed drug eruptions with feprazone are linked to HLA-B22","volume":"36","author":"Pellicano","year":"1997","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"7456","key":"10.1002\/14651858.CD010891.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD010891.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/clpt.2011.79","article-title":"Phenotype standardization for immune-mediated drug-induced skin injury","volume":"89","author":"Pirmohamed","year":"2011","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD010891.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0091-6749(99)70243-5","article-title":"Association of HLA-DR11 with the anaphylactoid reaction caused by nonsteroidal anti-inflammatory drugs","volume":"103","author":"Quiralte","year":"1999","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD010891.pub2-BIB0062|cit62","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"1","key":"10.1002\/14651858.CD010891.pub2-BIB0063|cit63","first-page":"41","article-title":"Association of HLA-DR5 with mucocutaneous lesions in patients with rheumatoid arthritis receiving gold sodium thiomalate","volume":"21","author":"Rodriguez-P\u00e9rez","year":"1994","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD010891.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1081-1206(10)62997-3","article-title":"Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes","volume":"80","author":"Romano","year":"1998","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"4","key":"10.1002\/14651858.CD010891.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1399-0039.1986.tb00491.x","article-title":"HLA phenotypes and bullous cutaneous reactions to drugs","volume":"28","author":"Roujeau","year":"1986","journal-title":"Tissue Antigens"},{"issue":"9","key":"10.1002\/14651858.CD010891.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","article-title":"Genetic susceptibility to toxic epidermal necrolysis","volume":"123","author":"Roujeau","year":"1987","journal-title":"Archives of Dermatology"},{"issue":"19","key":"10.1002\/14651858.CD010891.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD010891.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD010891.pub2-BIB0069|cit69","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A editors. GRADE Working Group GRADE handbook gdt.gradepro.org\/app\/handbook\/handbook.html"},{"issue":"2","key":"10.1002\/14651858.CD010891.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/BCR.0b013e31820aafbc","article-title":"Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study","volume":"32","author":"Sekula","year":"2011","journal-title":"Journal of Burn Care & Research"},{"issue":"6","key":"10.1002\/14651858.CD010891.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1067\/mai.2002.123872","article-title":"Delayed-type hypersensitivity reaction to paraphenylenediamine is mediated by 2 different pathways of antigen recognition by specific alphabeta human T-cell clones","volume":"109","author":"Sieben","year":"2002","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD010891.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/phar.2196","article-title":"Abacavir hypersensitivity reaction reporting rates during a decade of HLA-B*5701 screening as a risk-mitigation measure","volume":"39","author":"Stainsby","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1002\/14651858.CD010891.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD010891.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenetics and Genomics"},{"issue":"5","key":"10.1002\/14651858.CD010891.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","article-title":"Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population","volume":"51","author":"Tassaneeyakul","year":"2010","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD010891.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2249.2008.03627.x","article-title":"Monitoring non-immediate allergic reactions to iodine contrast media","volume":"152","author":"Torres","year":"2008","journal-title":"Clinical and Experimental Immunology"},{"issue":"4","key":"10.1002\/14651858.CD010891.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/QAD.0b013e3282f37812","article-title":"HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz","volume":"22","author":"Vitezica","year":"2008","journal-title":"AIDS"},{"issue":"1","key":"10.1002\/14651858.CD010891.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000290775","article-title":"Occupational trichloroethylene hypersensitivity syndrome with human herpesvirus-6 and cytomegalovirus reactivation","volume":"221","author":"Watanabe","year":"2010","journal-title":"Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD010891.pub2-BIB0079|cit79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010891","article-title":"Genetic testing for prevention of severe drug-induced skin rash","author":"Alfirevic","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD010891.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T09:48:34Z","timestamp":1669456114000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010891.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Skin Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,7,17]]},"references-count":79,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010891.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,17]]}}}